United States · Wires & real time · PR Newswire
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential…
HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter,…
Read the full article on PR Newswire Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)
